Related Experiment Video

Updated: Aug 9, 2026

Quantifiable and Inexpensive Cell-Free Fluorescent Method to Confirm the Ability of Novel Compounds to Chelate Iron
05:36

Quantifiable and Inexpensive Cell-Free Fluorescent Method to Confirm the Ability of Novel Compounds to Chelate Iron

Published on: February 23, 2024

Iron: not a benign therapeutic drug

Taj Madiwale1, Erica Liebelt

  • 1Department of Pediatric Emergency Medicine, Children's Hospital of Alabama, University of Alabama School of Medicine, Birmingham, Alabama 35233, USA. tmadiwale@peds.uab.edu

Current Opinion in Pediatrics
|April 8, 2006
PubMed

Insights

Iron poisoning is diagnosed clinically, with specific guidelines for children. Unit-dose packaging may reduce iron exposure and fatalities, highlighting prevention

Area of Science:

  • Toxicology
  • Pediatric Emergency Medicine
  • Public Health

Background:

  • Iron poisoning is a significant cause of pediatric morbidity and mortality.
  • Understanding the pathophysiology and clinical presentation is crucial for effective management.
  • Recent advancements in guidelines and preventative measures are essential for public health.

Purpose of the Study:

  • To review the pathophysiology and clinical presentation of iron poisoning.
  • To discuss updated guidelines for triage and management of pediatric iron ingestion.
  • To evaluate diagnostic and treatment modalities, including preventative strategies like unit-dose packaging.

Main Methods:

  • Review of existing literature on iron poisoning.
  • Analysis of recently proposed evidence-based consensus guidelines.
  • Examination of data on the impact of unit-dose packaging on iron exposure rates.

Main Results:

  • Carbonyl iron demonstrates a higher safety margin compared to iron salts, with no reported serious or fatal poisonings.
  • The established threshold for healthcare referral is 40 mg/kg of elemental iron from adult formulations.
  • Unit-dose packaging of iron products was associated with a reduction in iron exposures and fatalities in the US.

Conclusions:

  • Iron poisoning diagnosis relies heavily on clinical presentation, supported by laboratory and radiological findings.
  • Primary prevention strategies, such as unit-dose packaging, are paramount in reducing iron poisoning-related morbidity and mortality.
  • Adherence to updated triage and management guidelines is critical for optimal patient outcomes.
Abstract

Related Concept Videos

Therapeutic Index01:13

Therapeutic Index

The therapeutic index of a drug is a key parameter in pharmacology that quantifies the relative safety of a drug by calculating the ratio between the dose that causes toxicity in half the population (50%) to the dose that proves to be effective for half the population (50%). It provides a spectrum of doses for a particular drug ranging from effective to potentially toxic. To illustrate, consider an anticoagulant agent like warfarin. It possesses a narrow window within its therapeutic index to...
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Heart Failure Drugs: Inotropic Agents01:26

Heart Failure Drugs: Inotropic Agents

Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
Inhibitors of Viral Protein Synthesis01:30

Inhibitors of Viral Protein Synthesis

Protein synthesis is indispensable for viral replication, as viruses lack the cellular machinery required for this process and must hijack the host's translational apparatus. In response, host cells deploy a critical innate immune defense involving interferons, specialized cytokines that play a central role in inhibiting viral propagation.Upon viral detection, infected cells release interferons that bind to receptors on adjacent uninfected cells, activating the JAK-STAT signaling pathway and...
Drug toxicity: Drug–Drug Interaction01:30

Drug toxicity: Drug–Drug Interaction

Drug–drug interactions can precipitate toxicity through multiple mechanisms. Absorption interactions alter how drugs enter the body, exemplified when ranitidine increases the absorption of basic drugs, while cholestyramine decreases the levels of propranolol. Protein binding interactions occur when drugs share the same binding sites on plasma proteins. Drugs like aspirin and warfarin, when bound in excess, can lead to increased free drug concentrations, enhancing the potential for...
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents01:29

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel Disease...